We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Stealth BioTherapeutics Seeks Approval of Elamipretide Despite FDA Misgivings
Stealth BioTherapeutics Seeks Approval of Elamipretide Despite FDA Misgivings
Stealth BioTherapeutics is pursuing FDA approval for elamipretide, for treatment of Barth syndrome, a rare genetic disease, even though the FDA has said it needs to see data from an additional phase 3 study.